Compassionate Use of Investigational Drugs: A Strategy to Access Unapproved Therapies for Pediatric Oncology Patients Presented by BTG Speciality Pharmaceuticals by MIB Agents OsteoBites

Osteosarcoma Organoid Models: The Potential and Limitations of Personalized Avatars

Dr. Alice Soragni, PhD, is an Assistant Professor in the David Geffen School of Medicine at UCLA, a member of the Jonsson Comprehensive Cancer Center and of the UCLA Molecular Biology Institute. She has a Master of Science cum Laude from the University of Bologna, Italy and a PhD from the ETH of Zuerich, Switzerland. Her laboratory in the Department of Orthopaedic Surgery at UCLA couples basic research into mechanisms of disease to the development of novel therapeutic strategies. The lab focuses on developing tumor organoid models to investigate the biology of rare tumors and to perform screenings for precision medicine applications.

---

What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Reprogramming NK Cells Within the Tumor Microenvironment of Osteosarcoma Lung Metastases

Dr. Christian Capitini is an associate professor and the Jean R. Finley Professor of Pediatric Hematology and Oncology. He serves as co-leader of the Developmental Therapeutics Program at the University of Wisconsin Carbone Cancer Center and director of clinical innovation at the Forward BIO Institute. He has received many awards for his clinical and research contributions, including the Department of Pediatrics Gerard B. Odell Research Award, the Outstanding New Member Science Award from the Society for Pediatric Research (SPR), and the Janet Rowley Award from the Jonas Center Cellular Therapy Symposium at the University of Chicago. Nationally, Dr. Capitini is an active member of the Society for Immunotherapy of Cancer (SITC) and serves as at-large director. Additionally, he serves on the executive board for the Pediatric Real World chimeric antigen receptor (CAR) T Consortium.

Dr. Capitini leads an NIH-supported laboratory focusing on development of cell-based immunotherapies, including natural killer (NK) cells and CAR T cells, for the treatment of pediatric solid tumors. The Capitini Lab also develops alternatively activated macrophages for complications of bone marrow transplant, including graft-versus-host-disease (GVHD) and acute radiation syndrome. Dr. Capitini was one of the site principal investigators (PI) for the first multicenter CD19 CAR T cell trial, which led to the FDA approval of tisagenlecleucel-T (Kymriah) for relapsed/refractory B cell leukemia. Currently, he is site PI for a Kymriah trial related to the upfront treatment of high-risk B cell leukemia and for a multicenter GD2 CAR T cell trial for neuroblastoma and osteosarcoma through the Pediatric NCI-Cancer Immunotherapy Trials Network (CITN). He is also a sponsor and PI for a University of Wisconsin clinical trial expanding gamma delta T cells in vivo using zoledronate after alpha beta T cell depleted stem cell transplant.

---

What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

osTEAo- Returning to Yourself: Confidence and Identity as an AYA Cancer Patient

A cancer diagnosis can affect your ability to do the things you love, like sports, dance, and school, stripping your identity of your hobbies and passions. OsteoWarriors Camille and Mia chat about this loss of identity and how they cope.Listen in as they discuss what it's like dealing with a sense of loss of self and how they manage to form an identity outside of cancer.

---

What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

OSI Connect: Osteosarcoma Answers and Assistance

OSI Connect is the Osteosarcoma Institute’s free, easy-to-use resource for patients who have been diagnosed with osteosarcoma or suffered a relapse after initial treatment. In this OsteoBites episode, you will meet Lee J. Helman, MD, Director of the OSI and Chelsey Blanks, OSI Connect Administrator. You will learn how OSI Connect works and examples of how the program has helped more than 70 patients since its launch in 2019.

Lee J. Helman, MD has been studying the biology and caring for pediatric patients with sarcomas for over thirty years. Dr. Helman completed his post-doctoral training at the National Cancer Institute (NCI). He then became Head of the Molecular Oncology Section, Pediatric Oncology Branch, NCI, in 1993. He served as Chief of the Pediatric Oncology Branch from 1997-2007 and served as Scientific Director for Clinical Research in the Center for Cancer Research, National Cancer Institute from 2007 to 2016. He joined Children’s Hospital Los Angeles (CHLA) and the University of Southern California (USC) in 2017 as the Section Head of Basic and Translational Research within the Cancer and Blood Disease Institute (CBDI) and the Division of Hematology, Oncology and Blood and Marrow Transplantation. He remains an adjunct professor at CHLA. He has also trained many investigators in the field of pediatric sarcomas over the course of his career. He is currently focusing on improving outcomes in osteosarcoma as the Director of the Osteosarcoma Institute.

As the Osteosarcoma Institute Operations Manager, Chelsey Blanks schedules meetings for the board, oversees various operational aspects of the organization (including HR, IT, and office management), facilitates the grant cycle, and manages OSI Connect (formerly OSI Hotline) that offers free expert advice for osteosarcoma patients and families no matter where they are in their journey. Although Chelsey is Texan through and through, she spent six years living in Southern California and was thrilled to return to the homeland with her husband, Jordan, at the end of 2019. Chelsey obtained her undergraduate degree from the University of North Texas, where she studied Sociology, Philosophy, and Dance. Previously, she had an insurance and financial services career and was an Executive Assistant for her church in Orange County, California.

---

What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Open Clinical Trial: GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

*Please note : The safety and efficacy of GD2-SADA:177Lu-DOTA Drug Complex have not been established and have not been approved by health authorities in the US or globally.

Janet Yoon, M.D., specializes in pediatric hematology/oncology because it allows her to build long-term relationships with her young patients and their caregivers. Inspired by their resilience and strength, she stays at the leading edge of her field so that she can introduce families to the latest therapies, specifically those that minimize harmful and long-lasting side effects.

Dr. Yoon received her medical degree from the Medical College of Ohio and then served as a pediatric resident at the Medical University of South Carolina. She moved to California to pursue a pediatric hematology/oncology fellowship at Children’s Hospital Los Angeles. Prior to City of Hope, Dr. Yoon was at University of California Davis Medical Center then spent over a decade at University of California San Diego/Rady Children’s Hospital San Diego where she was a clinical professor and director of the pediatric solid tumor program. At Rady, she was honored twice with the Dr. William D. Roberts Pediatric Hematology Oncology Faculty Teaching Award.

Dr. Yoon’s research is dedicated to understanding and treating sarcomas, particularly in the adolescent and young adult population. She is actively involved in clinical trials.

---

What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

SCF-Skp2 Protein Complex as a Therapy for Osteosarcoma by Blocking the Mutational Effects of Rb and p53

Bang H. Hoang, MD, is a board-certified orthopedic surgeon specializing in musculoskeletal tumor surgery. Dr. Hoang is an expert in benign and malignant tumors, metastatic bone disease, pathologic fractures, complex bone and joint reconstruction with large-segment prosthesis and allograft, tumors of the pelvis and sacrum, and investigational therapy for bone and soft tissue sarcoma. He is the Co-Director of the Orthopaedic Oncology Division at Montefiore and Professor of Orthopaedic Surgery at Albert Einstein College of Medicine.

--

What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

osTEAo - Navigating Scanxiety

You are not alone - scanxiety is real! OsteoWarriors Camille and Mia chat about scans and share their experiences with the different types of scans, from x-rays to CT scans, to MRIs and PET scans. Listen in as they discuss what it's like adapting to life that is regularly punctuated with scans and share how they cope with scanxiety.

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Cold Atmospheric Plasma: A New Therapeutical Option for Osteosarcoma?

Cristina Canal Barnils (Barcelona 1977) is Associate professor at the Department of Materials Science and Engineering, at the Technical University of Catalonia (UPC), head of the PlasmaMedLab: Plasmas for BioMedical Applications Laboratory and of the Medical Technologies: Biomaterials & Tissue Engineering research group at the IRSJD.

Before joining UPC, she did different research stages at pre and postdoctoral level in different national and international research centres. She has participated and lead a number of research projects, as well as technology transfer projects in the areas of Textile materials, Biomaterials and Cold Plasmas. Her research has led to above 60 publications, and several invited conferences. Her research has been recognized with different awards, including the L’Oreal-Unesco fellowship “For Young Women in Science” (2012), the “2018 Early Career Award in Plasma Medicine“ and the ICREA Acadèmia 2020.

Her interests are focused in cold plasmas for biomedical applications, particularly: i. Surface modification of biomaterials to control parameters such as adhesion or biological behaviour; ii. Control of drug release from biomaterials; and iii. Therapeutical appications of cold plasmas, for instance, in bone cancers.

She is currently ERC APACHE project Starting Grant leader in a project in the field of atmospheric pressure plasma therapy, her main axis of research being currently focused in the atmospheric pressure plasma therapy of bone cancer treatment in combination with biomaterials.

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

UHRF1 Overexpression Promotes Osteosarcoma Metastasis through Altered Exosome Production and AMPK/SEMA3E Suppression

Dr. Claudia Benavente studied Molecular Biotechnology Engineering at Universidad de Chile where her interest in pursuing cancer research first started. To further her studies, she came to the US to pursue a doctoral degree in Cancer Biology at The University of Arizona as a Fulbright scholar. She then moved on as a postdoctoral fellow to St. Jude Children’s Research Hospital in Memphis, TN where she became familiar with childhood solid tumors. Professor Benavente is currently an Associate Professor at the Departments of Pharmaceutical Sciences and Developmental and Cell Biology and a member of the Chao Family Comprehensive Cancer Center at the University of California, Irvine. Dr. Benavente’s research focuses on understanding how pediatric tumors form to design new ways to treat them. Her research aims to understand how genes are normally controlled in developing tissues and how epigenetic processes are perturbed to facilitate cancers to arise. This information guides her in the development of new therapies.

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiosurgery (SRS) for Sarcoma

Erin S. Murphy MD is an Associate Professor in the department of radiation oncology at the Cleveland Clinic. She completed residency at the Cleveland Clinic and a fellowship in pediatric radiation oncology at St. Jude Children’s Research Hospital. She specializes in radiotherapy and radiosurgery for brain tumors and pediatric tumors and is passionate about using aggressive local tools while maintaining quality of life for her patients.

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

osTEAo - Navigating Campus: Limb-Salvage and Amputation Patient Perspectives

OsteoWarriors Camille and Mia are joined by OsteoWarriors Daniel and Kara in this episode on navigating life and campus with limb salvage surgery and amputation, which are the primary treatment options to remove an osteosarcoma tumor. Listen in as they discuss why they chose limb salvage surgery or amputation and how they manage getting around school, and share challenges and horror stories they've experienced which are sure to make you both grimace and laugh.

---

Save the Date and mark your calendars for FACTOR 2023 - June 22-24 in Atlanta GA. Registration is now live! Go to MIBAgents.org to register.

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org
Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks

Dr. Kelly M. Bailey MD, PhD, is a pediatric oncologist certified by the American Board of Pediatrics. She is assistant professor of pediatrics at the University of Pittsburgh School of Medicine. Dr. Bailey received her medical degree and PhD from West Virginia University, Morgantown, W.Va., and completed her residency in pediatrics and fellowship in pediatric hematology/oncology at the University of Michigan School of Medicine, Ann Arbor, Mich. Dr. Bailey’s clinical and research interests focus on pediatric sarcomas, specifically Ewing sarcoma. Nationally, Dr. Bailey is active in the Children’s Oncology Group Bone Tumor Committee and the New Agents for Ewing Sarcoma Task Force.

Dr. Bailey’s studies the rare primary pediatric bone tumor Ewing sarcoma. Her research focuses on understanding the intersection of DNA damage and immunoregulation of this tumor.

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

SarcoSIGHT- A Randomised Controlled Trial of Fluorescence Guided Sarcoma Surgery versus Standard Care

Surgery along with chemotherapy is the mainstay of treatment for patients with osteosarcoma. In order to achieve a cure, during surgery healthy tissue surrounding the tumour is also removed. Whilst this reduces the chances of the cancer returning, it can also result in added pain and disability for patients, impacting their quality of life in the longer-term. Advancements in surgical technology and technique offer the hope of improved outcomes for patients.

Recent developments have led to the introduction of fluorescence guided surgery (FGS), a technique which harnesses the emission of light to identify a tumour’s precise location and boundaries during surgical removal. This improves a surgeon’s ability to successfully remove the entire tumour, which can be identified as a ‘glowing’ area of tissue, decreasing the likelihood of any cancer cells remaining, while limiting the removal of too much healthy tissue.

This upcoming clinical trial, led by Kenneth Rankin, a leading Consultant Orthopaedic Surgeon and bone sarcoma researcher, is looking to assess the effectiveness of a particular fluorescent dye, indocyanine green or ‘ICG’, which can be given to patients safely before surgery and leads to the sarcoma tumour fluorescing green. The SarcoSIGHT trial will recruit 500 patients undergoing surgery for bone and soft tissue sarcoma, aiming to test whether the use of ICG in FGS can help to accurately identify the tumour, aid in complete removal and reduce the amount of healthy tissue removed.

This presentation will include the findings to date from fluorescence guided surgery in osteosarcoma patients with some initial results indicating that the amount of fluorescence may predict response to chemotherapy and that the osteosarcoma tissue can be studied in detail post-operatively with the latest fluorescence microscopy techniques.

---

Mr Kenneth Rankin is a Consultant Orthopaedic Surgeon at Newcastle’s Freeman Hospital where his specialist interests are in orthopaedic oncology including fluorescence guided surgery for sarcoma resection, and hip and knee replacement for arthritis.

Mr Rankin graduated in 1999 from the University of Dundee. His basic surgical training was in Newcastle followed by an MD investigating the cellular biology of bone metastases. Mr Rankin completed his higher specialist training in Perth and Dundee followed by a return to the North East as NIHR Academic Clinical Lecturer.

His current post as Consultant Orthopaedic Surgeon and Honorary Senior Lecturer is comprised mainly of orthopaedic oncology including the surgical management of bone and soft tissue sarcomas and metastatic bone disease. He also carries out hip and knee replacements for arthritis. As a Clinical Scientist Mr Rankin has developed an international reputation for translational research for the detection of circulating tumour cells in sarcoma patients and carried out the world’s first case series of fluorescence guided surgery in sarcoma. Working in close collaboration with scientists at Newcastle University, he leads on basic and translational sarcoma research at the Newcastle Centre for Cancer.

Virtual Surgical Planning and 3D Printing in Pediatric Musculoskeletal Oncological Resections

Jayanthi Parthasarathy BDS, MS, PhD, manages the 3D Printing Lab at Nationwide Children’s Hospital, which provides comprehensive patient-specific treatment planning and device development services from a pediatric perspective. She will discuss virtual surgical planning and 3D printing in pediatric musculoskeletal oncological resections.

A trained dental surgeon with more than 3 decades of practice, Dr. Parthasarathy is a pioneer in additive manufacturing for clinical needs, specializing in the development of patient-specific medical devices using advanced design and manufacturing technologies, having used the technology for more than 2 decades. With a masters in manufacturing and a doctorate in industrial engineering has researched on design and manufacturing of patient-specific devices using 3D printing and material composition for medical 3D printing. Dr. Parthsarathy worked in the medical device industry specializing in bringing to market patient-specific implantable and non-implantable adult and pediatric devices from ideation to production. She is currently managing the point of care 3D printing program in the department of radiology at Nationwide Children’s Hospital in Columbus, Ohio, U.S.A - one of the largest pediatric referral hospitals in the country. She works with all specialties across the board, cardio-thoracic, plastic and reconstructive, orthopedic, neuro, oncologic and pediatric surgeons for virtual surgical planning, design, and manufacturing of patient-specific devices for surgical guidance and simulation.

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Two Epigenetically Distinct Cellular States in Osteo are Regulated by a State-Specific Set of Transcription Factors Driving Differential Drug Response

Eunice Lopez Fuentes is in her postdoc studies at UCSF in Sweet-Cordero Lab. She is interested in defining the mechanisms of epigenetic gene regulation in osteosarcoma. Fuentes has uncovered two epigenetic different cell states with differential drug responses. Her main goal is to gain insight into the biology of these subclasses and define how their distinct master regulators may determine new clinically relevant vulnerabilities.

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Clinical Trial: Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Marie Nelson, M.D., is originally from Michigan, attended college at the University of Notre Dame and earned her medical degree from Loyola University Chicago Stritch School of Medicine. She finished her residency in Pediatrics at Ann & Robert H. Lurie Children’s Hospital of Chicago prior to completing a fellowship in Pediatric Hematology, Oncology, and Bone Marrow Transplantation at Children’s National Hospital in Washington, D.C. Dr. Nelson is a member of the solid tumor faculty and Assistant Professor of Pediatrics at Children’s National Hospital where she also leads the Adolescent and Young Adult Oncology Program. Her research focuses on combining local therapies and immunotherapy in order to improve the outcomes and reduce the side effects of treatment for pediatric patients with solid tumors.

She is the principal investigator of a phase II trial combining cryoablation and immune checkpoint inhibitors in pediatric solid tumors.

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Cell Based Therapies for Osteosarcoma

Michael Leibowitz is an Assistant Professor in Hematology/Oncology/BMT and Cellular Therapeutics at Children's Hospital of Colorado. He is a physician-scientist whose research focuses on developing novel and effective cellular therapies for solid tumors including osteosarcoma.

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

osTEAo Q&A with Dr. Kurt Weiss - What questions do you have about Osteosarcoma but are afraid to ask?

OsteoWarrior Mia and her mom Serena have a frank conversation with orthopedic oncologist and OsteoWarrior Dr. Kurt Weiss from the University of PIttsburgh. They discuss questions patients and caregivers often have about Ostesosarcoma but are afraid to ask.

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org
Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Interventional Radiology/HIFU Perspectives for Osteosarcoma

Karun V. Sharma, M.D., Ph.D., is the Director of Interventional Radiology at Children's National Hospital, and an Associate Professor of Pediatrics and Radiology at the George Washington University School of Medicine and Health Sciences. His clinical practice and translational research focuses on minimally invasive image-guided therapies for musculoskeletal and oncology conditions. Dr. Sharma leads the Image-Guided Non-Invasive Therapeutic Energy (IGNITE) program, a collaboration of the Sheikh Zayed Institute and the departments of Radiology, Oncology, Surgery, and Anesthesiology at Children’s National Hospital. The IGNITE program aims to improve the quality of life and outcomes for pediatric patients through the development and clinical translation of novel minimally invasive and noninvasive surgery technologies and combination therapy approaches, with the ultimate goal of making pediatric surgery more precise, less invasive and pain-free. In the recent years, Dr. Sharma and the IGNITE team have developed Magnetic Resonance Imaging –guided High Intensity Focused Ultrasound (MR-HIFU) applications for pediatric patients and lead clinical trials for osteoid osteoma and other tumors.

AeRang Kim, M.D., Ph.D., is a member of the solid tumor faculty at Children’s National Hospital and an Associate Professor of Pediatrics. Dr. Kim's specializes in sarcomas and developmental therapeutics. Her research focuses on development of novel therapeutics for pediatric cancer including pre-clinical testing of novel agents, pharmacokinetic analysis, developing innovative methods for toxicity monitoring and clinical trial design. She serves as the principal investigator of multiple early phase trials in pediatric oncology, sarcomas and NF1 associated tumors.

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Focal Adhesion Kinase (FAK) Inhibition to Improve Losartan-Sunitinib Immunotherapy in Metastatic Osteosarcoma

Dr. Dan Regan discusses his OutSmarting Osteosarcoma funded work on Focal Adhesion Kinase (FAK) inhibition to improve losartan-sunitinib immunotherapy in metastatic osteosarcoma.

-

Dr. Dan Regan is an Assistant Professor at the Flint Animal Cancer Center at Colorado State University and he is one of our OutSmarting Osteosarcoma 2022 grant recipients. Dr. Regan received his DVM degree from the University of Georgia and subsequently completed his residency training in veterinary anatomic pathology and PhD in the Department of Microbiology, Immunology, and Pathology (MIP) at Colorado State University. In 2018 he joined the Flint Animal Cancer Center and MIP in the College of Veterinary Medicine and Biomedical Sciences at Colorado State University. The focus of Dr. Regan’s laboratory is to increase our understanding of the interplay between the immune system and (non-immune) tumor stroma, and how these compartments of the tumor microenvironment promote metastasis as well as respond to and mediate extrinsic mechanisms of resistance to anti-cancer therapy. To investigate this area of cancer biology, his laboratory utilizes a combination of in vitro 3-dimensional tumor co-culture models and animal models, focusing on breast and bone cancer (osteosarcoma). Dr. Regan also has a strong interest in comparative oncology and leveraging naturally occurring cancers in dogs as both a surrogate and intermediary model to evaluate and validate his laboratory’s investigations into the tumor microenvironment. In collaboration with the laboratory of Dr. Steve Dow, his lab conducted immunotherapy clinical studies in dogs with spontaneous osteosarcoma and these study results have led to a phase I clinical trial in children with osteosarcoma. His lab’s continued long-term research goal is to fully elucidate the mechanisms by which tumors prime non-malignant host stromal cells of distant organs to promote their metastasis and chemo-resistance, in order to identify novel targets for host-directed stromal therapies which “poison the soil” for effective combination with conventional tumor cell targeted drugs.

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org
Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Updates from Clinical Sequencing of 2,138 Bone and Soft Tissue Sarcomas

This episode is sponsored by BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications.

---

Benjamin Nacev, MD PhD is a physician-scientist with an interest in sarcoma biology. His work focuses on understanding the causes of sarcomas with a goal of developing new treatments. Dr. Nacev completed his MD and PhD training at the Johns Hopkins University School of Medicine, where he also trained in Internal Medicine. He moved to Memorial Sloan Kettering where he completed his Medical Oncology Fellowship and later joined the faculty before moving to the University of Pittsburgh School of Medicine and the UPMC Hillman Cancer Center.

-

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

osTEAo Presents Halloween Spooky Stories

Mia and Vicky talk about unexpected complications during their cancer journey and how they were able to cope, and what could’ve done to ease it beforehand in this raw, real conversation spilling the tea on osteosarcoma, and AYA cancer.

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

How Osteosarcoma Evolves from Diagnosis to Relapse

This episode is sponsored by the Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure ® for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Our osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions.

-

Dr. Kinnaman is current a member of the Pediatric Sarcoma Service at Memorial Sloan Kettering Cancer Center (MSKCC) where he specializes in taking care of children, adolescents, and young adults diagnosed with pediatric sarcomas. He is a member of the Iacobuzio-Donahue Lab Group, with research efforts focused on describing and detailing the clonal evolution of cancer cells in pediatric sarcomas. Dr. Kinnaman has been the recipient of a number of young investigator awards to fund his research, with support from Hyundai Hope on Wheels, the Rally Foundation, ASCO/Conquer Cancer Foundation, and the QuadW Foundation. He has also been awarded a National Institutes of Health (NIH)/MSKCC K12 Paul Calabresi Career Development Award for Clinical Oncology. You can follow him on Twitter @MDKinnz and Instagram @mkinnaman

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Transforming the Way Researchers Share Data: Lessons from the Pediatric Cancer Data Commons

This episode is sponsored by BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications.

---

Dr. Volchenboum is an associate professor of pediatrics and the associate chief research informatics officer for the biological sciences division at the University of Chicago. He is the Dean of Masters Programs, and he designed and launched the UChicago Master’s in Biomedical Informatics. His clinical specialty is pediatric hematology / oncology, caring for kids with cancer and blood diseases. His research group includes the University of Chicago’s Pediatric Cancer Data Commons, a group dedicated to liberating and democratizing international data for pediatric malignancies. He is the director of the Informatics Core for the Clinical and Translational Science Award (CTSA), and he is director of the UChicago Clinical Informatics fellowship program.

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

osTEAo - Dating & Intimacy with Lauren Broschak, MSW, LCSW, OSW-C

Lauren Broschak is an oncology-certified Licensed Clinical Social Worker who joined the Life with Cancer team in May 2019. She received her Master’s degree in social work from the University of Michigan, where she specialized in clinical practice and health. She provides therapeutic support, resources and education to patients and their caregivers. Lauren serves as the Co-Chair for the Association of Oncology Social Work Adolescent and Young Adult (AYA) Special Interest Group, and has spoken at national conferences regarding the impact of cancer on AYAs. She has completed training through the Enriching Communication Skills for Health Professionals in Oncofertility (ECHO) program, and is currently attending the University of Michigan’s Sexual Health Certificate Program specializing in sex therapy and sexuality education. Her areas of interest include AYAs impacted by cancer, illness’ effect on sexuality, intimacy and fertility, couples and cancer, dating and cancer, and caregiver support.

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Overcoming PD-1 Inhibitor Resistance with a Monoclonal Antibody to Secreted Frizzled-Related Protein 2 in Metastatic Osteosarcoma

We would like to thank the sponsor of this episode, BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. Their drug, Voraxaze, is for high-dose methotrexate toxicity.

---

Dr. Nancy DeMore is a board-certified breast surgical oncologist and is the BMW endowed chair in cancer research at MUSC Health. Dr. DeMore obtained her medical degree from Chicago Medical School. She completed her residency at Boston University Medical Center, a cancer research fellowship at Harvard Medical School, and fellowship training at Memorial Sloan Kettering Cancer Center. Dr. DeMore practiced as a professor of surgery at the University of North Carolina-Chapel Hill for 13 years.

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Report on the Phase I/II Study of Single-Agent Lenvatinib in Children and Adolescents with Refractory or Relapsed Solid Malignancies and Young Adults with Osteosarcoma

This episode is sponsored by the Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure ® for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Our osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions.

---

Dr. Nathalie Gaspar, MD, PhD, is a pediatric oncologist at Gustave Roussy Cancer Campus (Villejuif, France), head of the adolescent and young adult (AYA) unit and chair of the AYA program of the institute (SPIAJA program), since 2009. She is in charge of bone sarcomas, cancers with peak incidence in the AYA population, from biology to clinical care. Dr Gaspar is also pediatric head of the French bone adult and pediatric sarcoma group, GROUPOS. She is actively involved in early new drug development in France and in Europe, through her participation to the clinical trial committee of the Innovative Therapeutics for Child and adolescent with Cancer (ITCC) consortium and through her action as co-chair of the Fostering Age Inclusive Research (FAIR) trial initiative of the multi-stakeholder ACCELERATE platform.

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Inhaled Recombinant Human IL-15 in Dogs with Naturally Occurring Pulmonary Metastases from Osteosarcoma or Melanoma: a Phase 1 Study

This episode is sponsored by BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications.

---

Dr. Canter is a Surgical Oncologist with clinical expertise in the multidisciplinary management of sarcomas. He also runs a translational research laboratory which focuses on the therapeutic and mechanistic effects of combining natural killer (NK) cell immunotherapy with other treatment modalities to overcome NK dysfunction in the tumor microenvironment of solid tumors, including sarcomas in both humans and dogs. He serves as the co-leader of UC Davis Comprehensive Cancer Center’s Comparative Oncology Program, and his laboratory is one of a select group of labs internationally which is studying canine NK cells, including first-in-dog studies of canine immunotherapy and adoptive transfer of NK cells in dogs with osteosarcoma.

Dr. Rebhun is a an Associate Professor in the Department of Surgical and Radiological Sciences at the Center for Companion Animal Health at the UC Davis School of Veterinary Medicine. His research focus is in the field of comparative and translational oncology, with specific interests in metastasis and novel therapeutics.

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Outsmarting OS 2021 Funded Research Update: Exploring Aldehyde Dehydrogenase and Androgen Receptor Actions to OutSmart Osteosarcoma Metastases

This episode is sponsored by BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications.

---

Dr. Weiss is a Founding Member of the Musculoskeletal Oncology Research Initiative (MORI), Pittsburgh Cure Sarcoma (PCS), the Pittsburgh Sarcoma Research Collaborative (PSaRC), and the Pittsburgh Center for Bone and Mineral Research (PCBMR). He is a peer reviewer for multiple journals including the Journal of the American Academy of Orthopaedic Surgeons, BioMed Central Cancer, Sarcoma, Cancer Research, International Journal of Cancer, and others. He is a former member of the NIH’s Center for Scientific Review Early Career Reviewer program. He has served on multiple National Cancer Institute Study Sections. He is a member of the Musculoskeletal Tumor Society (MSTS) for which he serves as Chair of the Research Committee and the Connective Tissue Oncology Society (CTOS), for which he has served on the Board of Directors.

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org
Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Back to School: OsteoWarrior and OsteoSibling Perspectives

Listen in on honest conversations as Osteosarcoma Warriors and survivors discusses all aspects of the young adult cancer experience in this brave and frank podcast.

--

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Combination Therapies to Improve Immune-Mediated Approaches for Osteosarcoma

Dr. Yustein is a pediatric oncologist and physician-scientist with significant training in molecular and cellular biology. During his time as the Director of the Faris D. Ewing Sarcoma Center at Texas Children's Hospital, he recognized the need for improving our understanding of the molecular pathogenesis of sarcomas and the identification of new therapeutic avenues, especially for patients with therapeutic resistant and/or metastatic disease. His laboratory has tremendous interest and experience in merging innovative murine models and patient-derived resources towards garnering molecular insights into sarcoma initiation, development/resistance and metastatic progression and translating these findings towards testing novel therapeutic interventions for these aggressive malignancies. His laboratory has developed and characterized robust metastatic genetically engineered mouse models (GEMM) for pediatric sarcomas, including osteosarcoma (OS), which recapitulate the human disease initiation and progression. Subsequently, his lab has derived primary sarcoma lines from the GEMM tumors that can be orthotopically transplanted into wild type C57BL/6 mice and monitored using in vivo imaging for further characterization of sarcoma development and progression. He recently moved to Atlanta to join Emory University as a Professor in the Department of Pediatrics, Hematology-Oncology Division and the Director of Solid Tumor Translational Research Children’s Healthcare of Atlanta and the Aflac Cancer and Blood Disorders Center.

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Using RNA-Nanoparticle Vaccines to Overcome the Immunosuppressive Tumor Microenvironment of Canine Osteosarcoma

This episode is sponsored by the Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure ® for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Our osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions.

--

John A. Ligon, MD, is an assistant professor in the department of pediatrics at the University of Florida College of Medicine. Dr. Ligon earned his medical degree from the Baylor College of Medicine in Houston. After he completed his residency in pediatrics at the University of Texas Southwestern Medical Center in Dallas, he pursued a fellowship in pediatric hematology and oncology at Johns Hopkins University and the National Cancer Institute in Maryland. In the following years, he completed a senior fellowship in pediatric immunotherapy at the National Cancer Institute and another in pediatric sarcoma at Johns Hopkins University.

Dr. Ligon is board-certified in both general pediatrics and pediatric hematology and oncology by the American Board of Pediatrics. In addition to his numerous original research publications and editorial review appointments, he is a member of various professional societies, such as the Children’s Oncology Group and the American Association for Cancer Research. Dr. Ligon has been honored with a variety of awards for his research skills and academic excellence. His research interests include immunotherapy, tumors and bloodstream infections.

COG Project: Every Child - Episode Sponsored by Osteosarcoma Institute

This episode is sponsored by the Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure ® for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Our osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions.

A pediatric oncologist and physician-scientist, Dr. Crompton is the Research Co-Director of the Solid Tumor Center at Dana-Farber/Boston Children’s Cancer and Blood Disorder Center and he is an Assistant Professor of Pediatrics at Harvard Medical School. His research focuses on utilizing genomic and proteomic technologies to identify and validate new therapeutic targets for pediatric solid tumors and to develop non-invasive biomarkers of treatment response and resistance in these diseases. His lab has developed new approaches to estimating circulating tumor DNA levels from liquid biopsy samples from patients with pediatric solid tumors. He joins us on OsteoBItes to discuss a Children’s Oncology Group registry initiative called Project:Everychild.

--

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org
Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Body Image for AYAs with Cancer with Dr. Lori Weiner

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Unanswered Clinical Questions in Sarcoma: Opportunities to Move from Bedside to Bench - Episode Sponsored by Osteosarcoma Institute

This episode is sponsored by the Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure ® for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Our osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions.

Dr. Chris Collier is a dedicated surgeon-scientist who leads innovative basic science and clinical research to improve outcomes for his patients. He is an Assistant Professor of Orthopaedic Surgery at the Indiana University School of Medicine. He has authored numerous publications, textbook chapters, earned multiple research awards and grants, and presented his research nationally and internationally.

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Molecular Profiling Identifies Targeted Therapy Opportunities in Pediatric Solid Cancer - Episode Sponsored by Osteosarcoma Institute

This episode is sponsored by the Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure ® for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Our osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions.

Join us for OsteoBites with Dr. Alanna Church from Boston Children's Hospital. She will discuss the study recently published in Nature Medicine with Dr. Katie Janeway and many other collaborators, demonstrating the clinical utility of molecular tumor profiling for children with cancer. This cohort includes 345 children and AYA cancer patients from 12 institutions who had molecular tumor profiling using targeted NGS panels, including 64 patients with osteosarcoma. Molecular alterations with potential impact on the diagnosis, prognosis or treatment were identified in 86% of patients. She hopes these results will help to advocate for molecular profiling for all children with cancer. Read the paper here: https://rdcu.be/cQgmj

Reminder that this July for Sarcoma Awareness month, join us for our Virtual OutRunning OsteoSarcoma event! When you run/walk/cycle with us, you can help Cause A Cure. With MIB, no one walks through Osteosarcoma alone - let’s go OutRunning together! Register at: https://mibagents.swoogo.com/OutRunning

Also to commemorate Sarcoma Awareness Month, MIB is partnering with Kendra Scott for a Multi-City give back event taking place the weekend July 15-17! By making a purchase during this weekend, you are helping raise funds and awareness for Osteosarcoma.

This September, we encourage you to Be Bold and Go Gold for Childhood Cancer Awareness Month! Make & Sell Bows in your community OR Make a donation this summer and get a bow that shows you care. Contact anita@mibagents.org to volunteer today!

Navigating Pediatric Cancer Clinical Trials

Learn more about the clinical trial process, tips for finding all possible trials, and considerations when choosing a trial.

Brenna Carswell, a childhood cancer survivor and mother of two, holds a Master's degree in Counseling Psychology. Although oncology has been a key part of her life for over 30 years, she has worked directly with patients, families, researchers, and clinicians for the last 8 years. Along with pediatric cancer research and trials, Brenna is passionate about humanitarian causes and child welfare. She makes time for fun and escapes to the beach with her daughters as often as possible.

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Update on OSI funded phase 2 Trial of Olaparib + Ceralasertib in Recurrent Osteosarcoma

This episode is sponsored by the Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Our osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions.

Dr. Janeway received her medical degree from Harvard Medical School in 2000. She subsequently completed her residency in Pediatrics at Children's Hospital, Boston. She was a Chief Resident at Children's Hospital, Boston, and then completed her fellowship in Pediatric Hematology-Oncology at Dana-Farber Cancer Institute / Children's Hospital, Boston. In 2007, Dr. Janeway joined the staff of Dana-Farber and Children's Hospital, Boston, where she is a pediatric hematologist-oncologist and investigator with a research focus of pediatric sarcomas.

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org
Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Limb Salvage Surgery for OS: Patient & Surgeon Perspectives sponsored by the Osteosarcoma Institute

This episode is sponsored by the Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure ® for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Our osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions.

Dr. John Healey, Chief, Orthopaedic Service; Stephen McDermott Chair in Surgery, is an orthopaedic surgeon who specializes in caring for people with sarcomas and noncancerous tumors of the bones and soft tissue. He has particular expertise in removing tumors while preserving limbs, as well as a special interest in treating children who have bone cancers, such as osteosarcoma and Ewing sarcoma. Dr. Healey has been with Memorial Sloan Kettering since 1984 and performs approximately 260 surgeries each year. In addition to his role as Chief of the Orthopaedic Service at MSK, he is a professor of orthopaedic surgery at Weill Cornell Medical College. Nationally, he has served as chair of the Children’s Oncology Group Orthopaedics Section, president of the International Society of Limb Salvage, and president of the Association of Bone and Joint Surgeons, as well as on the boards of several musculoskeletal and orthopaedic organizations. Dr. Healey is also an advisor to the National Comprehensive Cancer Network.

Brandon was diagnosed with Osteosarcoma in the left proximal Tibia in January 2019, between his first and second semesters of senior year at the University of Maryland. He completed the standard 9 month chemotherapy roadmap and received limb salvage surgery in April 2019, completing treatment in October 2019. He graduated with his class in May 2019 and ultimately moved to Manhattan where he now works for Citibank. He has been cancer free (knock on wood) for 2.5 years.

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

"Armored" CAR T cells for Osteosarcoma sponsored by BTG Specialty Pharmaceuticals

This episode is sponsored by BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. Their drug, Voraxaze, is for high-dose methotrexate toxicity.

This session focuses on a Phase I Trial of GD2.CAR T Cells Combined with a Novel Interleukin-7 Signal.

Dr. Bilal Omer is a physician at Texas Children’s Cancer Center. In 2013, he completed his fellowship training in pediatric hematology-oncology. Dr. Omer is a member of the Bone Marrow Transplant (BMT)/Stem Celll Transplant Program and Medical Director at the Center for Cell and Gene Therapy at Texas Children's Hospital/Baylor College of Medicine. His is the principal investigator on currently 4 clinical trials for cell therapy.

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Immunotherapy for Osteosarcoma - Where Do We Go From Here? Sponsored by BTG Specialty Pharmaceuticals

This episode is sponsored by BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. Their drug, Voraxaze, is for high-dose methotrexate toxicity.

Dr. Breelyn A. Wilky, MD is a sarcoma medical oncologist and clinical trialist with research interests in immunotherapy, targeted therapy and precision medicine, and early phase drug development. She is Associate Professor and Director of the Sarcoma Program at the University of Colorado School of Medicine, and is a member of the Phase One and Experimental Molecular Therapeutics (POEMS) research program. As the Deputy Associate Director of Clinical Research for the University of Colorado Cancer Center, she leads the investigator-initiated clinical trials committee to help advance novel research to the clinic. Her laboratory studies the tumor and immune microenvironment of sarcomas, to identify new drugs that boost the immune system for future clinical trials in sarcoma.

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

The Osteosarcoma Project sponsored by BTG Specialty Pharmaceuticals

This episode is sponsored by BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. Their drug, Voraxaze, is for high-dose methotrexate toxicity.

Corrie Painter is the Deputy Director of Count Me In and is a research scientist at the Broad Institute of MIT and Harvard. A trained cancer researcher with a Ph.D. in biochemistry, she completed her postdoctoral work in cancer immunology, focused on melanoma. In 2010, Painter was diagnosed with angiosarcoma. She has combined her cancer advocacy and scientific background to engage with patients in order to build and carry out patient-partnered genomics studies. She is also the co-founder of Angiosarcoma Awareness Inc.

Taylor Cusher is a clinical project manager with Count Me In at the Broad Institute of MIT and Harvard. In this role she manages several patient-partnered research studies that generate and share clinical, genomic, and patient-reported data for rare cancers. Prior to joining the Broad Institute, Cusher led programs on patient access to health data and patient engagement in medical R&D at FasterCures, a center of the Milken Institute. In these roles, her passion for enhancing connection and community at the intersection of patients and research is at the forefront of her work. Cusher holds a BS in kinesiology from the University of Massachusetts Amherst and a Master's degree in public health from the George Washington University.

Exploring the Use of a Predictive Tool for Methotrexate Clearance sponsored by BTG Specialty Pharmaceuticals

This episode is sponsored by BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. Their drug, Voraxaze, is for high-dose methotrexate toxicity.

Brooke Bernhardt, PharmD, MS, BCOP, BCPPS is an Assistant Professor in the Department of Pediatrics, Section of Pediatric Hematology/Oncology at Baylor College of Medicine in Houston, Texas and the Director of Pharmacy for Global HOPE (Hematology/Oncology Pediatric Excellence). Her research interests include improving pharmacy practice globally with a focus in Sub-Saharan Africa, ethical and practical strategies for managing and mitigating medication shortages, health disparities in pediatric oncology, and the role of pharmacogenomics in pediatric oncology. She has a particular interest in antimetabolite disposition and the impact of host-related factors on toxicity and clinical outcomes.

MYC Amplification as a Prognostic Biomarker in Osteosarcoma Sponsored by BTG Speciality Pharmaceuticals

This episode is sponsored by BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. Their drug, Voraxaze, is for high-dose methotrexate toxicity.

This talk will focus on research elucidating MYC amplification as the first genomic prognostic biomarker in osteosarcoma, which may be used for risk stratification in future clinical trials and to inform conversations with patients and families. Dr. Marinoff will discuss the tools used to detect MYC amplification, what we have learned about its association with outcome in children/ young adults with osteosarcoma, and what we still don't know but are trying hard to find out: the biological roles of MYC amplification in driving osteosarcoma and how it may serve as a potential therapeutic target in the future.

Dr. Marinoff graduated from Harvard Medical School and completed her pediatric residency at Boston Combined Residency Program, during which time she worked with Dr. Katie Janeway on elucidating the genomic landscape of and novel genomic biomarkers in osteosarcoma. She is currently completing her fellowship training in Pediatric Hematology/Oncology at UCSF, where she is focused on developing novel genome-informed therapeutics for osteosarcoma under the mentorship of Dr. Alejandro Sweet-Cordero. She plans to develop an active clinical and translational research program focused on conducting early phase precision medicine-oriented trials for patients with advanced sarcomas. She is grateful to have the best job in the world.

Compassionate Use of Investigational Drugs: A Strategy to Access Unapproved Therapies for Pediatric Oncology Patients Presented by BTG Speciality Pharmaceuticals

This episode is sponsored by BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications.

This presentation will explain the process and the challenges of obtaining access to experimental drugs for cancer patients.

Elena is Programs Director at Kids v Cancer, a nonprofit pediatric cancer advocacy organization. Elena directs the Compassionate Use Navigator program, providing guidance and personal assistance to physicians and families in applying for experimental drugs. Previously Elena worked as a science and business journalist, and as a program manager. Elena holds a Master of Public Health degree in maternal and child health and an M.A. degree in journalism.

The Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) International Randomized Controlled Trial Sponsored by BTG Specialty Pharmaceuticals

This episode is sponsored by BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications.

Dr. Michelle Ghert is a full Professor in the Department of Surgery, Division of Orthopaedic Surgery at McMaster University. She is Director of MacOrtho Research and co-Chair of the Sarcoma Disease Site at the Juravinski Cancer Center in Hamilton. Dr. Ghert completed her undergraduate and medical degrees at Stanford University and Vanderbilt University respectively. She trained in orthopaedic surgery at Duke University and completed a 2-year fellowship in orthopaedic oncology at the University of Toronto. She has been on Faculty at McMaster since 2005. Dr. Ghert has been selected to the Presidential Line of the Musculoskeletal Tumor Society and will be President-Elect in October of this year.

Dr. Ghert’s research initiatives have made national and international impact. She led the Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) randomized controlled trial (RCT), the first multi-centre RCT in orthopaedic oncology in which 604 patients were enrolled from 55 clinical sites in 12 countries. In terms of the number of countries collaborating, PARITY is the largest RCT in orthopaedic surgery to date. The study was published in the Journal of the American Medical Association (Oncology) on January 6, 2022. . Dr. Ghert is also leading the Surveillance After Extremity Tumor Surgery (SAFETY) RCT in which patients are randomized to more or less intense surveillance after treatment for a high-grade soft-tissue sarcoma. The primary outcome for the SAFETY trial is overall survival at 5 years. Similar to the PARITY trial, the SAFETY trial is an international multi-centre collaborative trial. Both the PARITY and SAFETY RCTs have been supported by research grants from the Canadian Institutes of Health Research (CIHR) and the Canadian Cancer Society Research Institute (CCSRI). For her work on the PARITY trial, Dr. Ghert was awarded the 2018 J. Éduoard Samson Award for Excellence in Orthopaedic Research by the Canadian Orthopaedic Foundation.

Dr. Ghert’s other research interests include the promotion of diversity and inclusion within the orthopaedic surgery workplace. She recently collaborated with the Canadian Orthopaedic Association (COA) on the study entitled ‘Prevalence of gender-based and sexual harassment in the field of orthopaedic surgery’, was recently published in the Canadian Journal of Surgery. She is also working with the COA on a study to determine the barriers to men and women in their participation in orthopaedic travelling fellowships.

Osteosarcoma Q&A with OsteoWarriors sponsored by BTG Specialty Pharmaceuticals

This episode is sponsored by BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications.

Matteo Trucco, MD is Director Children's Cancer Innovative Therapy Program Associate Staff, Peds Hematology-Oncology & BMT at Cleveland Clinic. He received his training in Pediatric Hematology/Oncology from John's Hopkins and the National Cancer Institute and has focused his career primarily on Pediatric Sarcomas and the development of new therapies.

Truths & Myths of Nutrition in Cancer sponsored by BTG Specialty Pharmaceuticals

This episode is sponsored by BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications.

With almost 25 years of experience as a registered dietitian nutritionist, Natalie is a well-seasoned practitioner. A board-certified specialist in oncology nutrition, Natalie is the founding dietitian for the nutrition program at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center and is the clinical nutrition specialist at Smith Integrative Oncology in San Francisco. On a daily basis, she works with patients through her integrative & functional nutrition private practice.

Natalie serves as a consultant and speaker for Digestive Care, Inc. and Kate Farms. As a member of the Lilly Lecture Bureau Faculty, Natalie regularly presents to health care practitioners on Nutritional Counseling in Oncology Care. She is a certified LEAP therapist who helps manage adverse food reactions with an emphasis on food sensitivities. Natalie provides nutrition counseling and frequently presents nationally on various cancer and integrative health focused nutrition topics. She has taught college courses and cooking classes, and has been extensively involved in community outreach.

Natalie is highly regarded in her industry and is often sought out for her expert opinion. She has been interviewed by The New York Times, NBC, Fortune magazine, Cure magazine, MAMM magazine, Runner’s World, and the San Francisco Chronicle. Recent publications include Oncology Nutrition for Clinical Practice (co-editor and author), Health & Wellness: Living with Prostate Cancer for the Prostate Cancer Foundation, and nutrition chapters in Clinical Nutrition for Oncology Patients, Everyone’s Guide to Cancer Therapy, Everyone’s Guide to Cancer Survivorship, Nutritional Issues in Cancer Care, and Supportive Cancer Care: The Complete Guide for Patients and their Families.

Amputation for OS; Patient & Surgeon Perspectives sponsored by BTG Speciality Pharmaceuticals

This episode is sponsored by BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. Their drug, Voraxaze, is for high-dose methotrexate toxicity.

Dr. Weiss is a Founding Member of the Musculoskeletal Oncology Research Initiative (MORI), Pittsburgh Cure Sarcoma (PCS), the Pittsburgh Sarcoma Research Collaborative (PSaRC), and the Pittsburgh Center for Bone and Mineral Research (PCBMR). He is a peer reviewer for multiple journals including the Journal of the American Academy of Orthopaedic Surgeons, BioMed Central Cancer, Sarcoma, Cancer Research, International Journal of Cancer, and others. He is a former member of the NIH’s Center for Scientific Review Early Career Reviewer program. He has served on multiple National Cancer Institute Study Sections. He is a member of the Musculoskeletal Tumor Society (MSTS) for which he serves as Chair of the Research Committee and the Connective Tissue Oncology Society (CTOS), for which he has served on the Board of Directors.

Kara Skrubis and was diagnosed with osteosarcoma in January of 2020. Kara received 9 months of chemotherapy, a left above the knee amputation, and then 8 months of immunotherapy. Currently, Kara is 20 years old living in Buffalo, New York attending the University at Buffalo pursuing a child life certification. In her free time Kara enjoys dancing, art, fostering dogs, photography, and her work with the MIB Junior Advisory Board serving as the 2022 president!

Human Trial for OST-HER2

Today we talk with Dr. Damon Reed from Moffit Cancer Center and Dr. Nicola Mason from University of Pennsylvania School of Veterinary Medicine about the promising results from a multi-institutional clinical trial evaluating the safety and efficacy of a recombinant Listeria to prevent metastatic disease in dogs with osteosarcoma, and how that will translate to a human trial. #clinicaltrials #osteosarcoma #cancerupdates

OsteoBites: Clinical Trials for Relapsed or Refractory Osteosarcoma - The OLIE Study and Beyond!

Join Dr Filemon Dela Cruz & Dr. Julia Glade Bender as they talk about The OLIE Study - Evaluating lenvatinib in combination with chemotherapy for relapsed or refractory osteosarcoma.
......
Organization Memorial Sloan Kettering Cancer Center/MSK Kids

What We Do at MIB Agents:
PROGRAMS:
✨ End-of-Life MISSIONS
✨ Gamer Agents
✨ Agent Writers
✨ Prayer Agents
✨ Healing Hearts Bereaved Parent Support
✨ Ambassador Agents - Peer Support
EDUCATION for physicians, researchers and families:
✨ OsteoBites webinar & podcast with thought leaders and innovators in Osteosarcoma
✨ MIB Book: Osteosarcoma: From our Families to Yours
RESEARCH:
✨ Annual MIB FACTOR Research Conference
✨ Funding $100,000 annually for OS research
✨ MIB Testing & Research Directory
✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard

LINKS:
OLIE Clinical Trial: LINK
🔗Memorial Sloan Kettering Cancer Center Pediatrics: LINK
📧 Filemon Dela Cruz, MD: delacrf1@mskcc.org
📧 Julia Glade-Bender, MD: gladebej@mskcc.org
🔗MIB Clinical Trial Finder In 60 seconds: LINK
🔗 MIB Programs: LINK
🔗 MIB Osteosarcoma FACTOR: LINK
🔗 MIB Osteosarcoma Research: LINK
...
Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org
🔗Donate HERE ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Real Talk: What it's really like and how WE feel about Osteosarcoma.

Osteobites: Junior Board, Like No One is Listening
MIB Junior Board Osteowarriors Ally & Kara, and OsteoSiblings Annika and Valerie have an honest conversation about osteosarcoma. This session is a no-holding-back conversation about unrestricted emotions, real experiences, and new realities.
#likenobodyislistening
...
What We Do at MIB Agents:
PROGRAMS:
✨ End-of-Life MISSIONS
✨ Gamer Agents
✨ Agent Writers
✨ Prayer Agents
✨ Healing Hearts Bereaved Parent Support
✨ Ambassador Agents - Peer Support

EDUCATION for physicians, researchers and families:
✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma
✨ MIB Book: Osteosarcoma: From our Families to Yours

RESEARCH:
✨ Annual MIB FACTOR Research Conference
✨ Funding $100,000 annually for OS research
✨ MIB Testing & Research Directory
✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard
...
Kids are still dying with 40+ year old treatments.
Help us MakeItBetter. 🔗 https://www.mibagents.org
Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate
✨SUBSCRIBE for all the Osteosarcoma Intel ✨

Planning for Dignity and What Matters Most to You

Paul Malley is President of Aging with Dignity, a national non-profit organization based in Tallahassee, Florida, with a mission to help individuals and their families receive the care they want in case of a serious illness.

As President of Aging with Dignity, Malley coordinates the national Five Wishes advance care planning program. Created by Jim Towey, founder of Aging with Dignity and former legal counsel to Mother Teresa of Calcutta, Five Wishes is an easy-to-use legal document that addresses important medical issues as well as personal, emotional and spiritual matters at the end of life. More than 35 million Americans have turned to Five Wishes as their preferred tool to make their wishes known and to discuss their preferences with their family and doctor before a health crisis. More than 40,000 partner groups (hospitals, hospices, places of worship, employers, community organizations) make up the growing network of organizations that distribute Five Wishes in communities across the country.

Paul Malley and the work of Aging with Dignity have been featured in national media including the CBS, NBC, and ABC evening news, CNN, MSNBC, NBC Today Show, Good Morning America, USA Today, The Wall Street Journal, The New York Times, Newsweek, Time, and Consumer Reports.

Malley has spoken about aging issues and advance care planning to organizations such as the US Departments of State and Justice, The Johns Hopkins University School of Medicine, The National Naval Medical Center at Bethesda, Florida Department of Education and Executive Office of the Governor, Delta Airlines, 3M, The National Foundation of Women Legislators, Employee Benefits Management Forum and the Alliance for Work/Life Progress.

Malley has also contributed to the efforts of several aging advocacy groups to improve state policy on advance care planning. He was appointed by Gov. Jeb Bush to the 2005 White House Conference on Aging.

VIDEO: LINK to the OsteoBites with Paul Malley. Please Subscribe PODCAST: LINK, and know that it is available wherever you get your podcast (Apple, Google+, Spotify, etc) just look for OsteoBites. Aging With Dignity YouTube Channel: LINK Voicing My Choices Page with Free Download: LINK Five Wishes Website: LINK

Paul Malley’s Email: Paul@FiveWishes.org
...
What We Do at MIB Agents:
PROGRAMS:
✨ End-of-Life MISSIONS
✨ Gamer Agents
✨ Agent Writers
✨ Prayer Agents
✨ Healing Hearts Bereaved Parent Support
✨ Ambassador Agents - Peer Support
EDUCATION for physicians, researchers and families:
✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma
✨ MIB Book: Osteosarcoma: From our Families to Yours
RESEARCH:
✨ Annual MIB FACTOR Research Conference
✨ Funding $100,000 annually for OS research
✨ MIB Testing & Research Directory
✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard
...
Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org
✨✨SUBSCRIBE for all the Osteosarcoma Intel

Let's Talk Fertility and Osteosarcoma

Dr. Abha Gupta discusses "Fertility Preservation in Osteosarcoma Patients" with Junior Board Members Kara, Valerie, and Alexis. We talk about it ALL.

Dr. Abha Gupta received her MD at the University of Toronto. She completed her pediatrics residency at Yale New Haven Children’s Hospital (New Haven, CT) and Children’s Hospital of Eastern Ontario (Ottawa) before moving back to Toronto to complete her fellowship in pediatric hematology/oncology at The Hospital for Sick Children. To complement her training, Dr. Gupta completed a one-year fellowship in Adolescent and Young Adult Oncology with a focus on sarcoma at Princess Margaret Cancer Centre. She is currently cross-appointed as a staff oncologist at both The Hospital for Sick Children (Solid Tumor Section) and Princess Margaret Cancer Center. She is the Medical Director of the Adolescent and Young Adult Oncology Program at Princess Margaret and Medical Director of the Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC).

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts Bereaved Parent Support ✨ Ambassador Agents - Peer Support EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: ✨ Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org✨✨SUBSCRIBE for all the Osteosarcoma Intel

How "Hydroxychloroquine and "self-eating" works with Osteosarcoma.

In this weeks Osteobites we join Dr. Andy Livingston & Dr. Nancy Gordon as they share their discussion and leading-edge research about how "Hydroxychloroquine and "self-eating" works with Osteosarcoma." After a short presentation on this research, they take questions from attendees. It's a can't miss Osteobites.

Hosted by: Ann Graham OsteoWarrior and Executive Director of MIB Agents

Youtube Video of this episode: https://youtu.be/OZKi0wxt9ns

What We Do at MIB Agents:

PROGRAMS:

✨ End-of-Life MISSIONS

✨ Gamer Agents

✨ Agent Writers

✨ Prayer Agents

✨ Healing Hearts Bereaved Parent Support

✨ Ambassador Agents - Peer Support EDUCATION for physicians, researchers and families:

✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma

✨ MIB Book: Osteosarcoma: From our Families to Yours RESEARCH:
✨ Annual MIB FACTOR Research Conference
✨ Funding $100,000 annually for OS research
✨ MIB Testing & Research Directory
✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments.

Help us MakeItBetter.

🔗 https://www.mibagents.org

Osteosarcoma Update from Dr. Huang - 2019 OutSmarting Osteosarcoma recipient

Dr. Huang is back on OSTEOBites to give us an update on his research funded by OutSmarting Osteosarcoma 2019. Don't miss this exciting new episode, plus who doesn't love Dr. Huang?

ABOUT Alex Huang, MD, PhD:
Dr. Huang received a B.S. in chemistry and an M.S. in biochemistry and molecular biology from the University of Chicago. He then entered the medical scientist training program at the Johns Hopkins University School of Medicine, where he completed his Ph.D. thesis in the laboratory of Drew M. Pardoll, M.D., Ph.D. Dr. Huang’s Ph.D. thesis included studying the process of in vivo tumor-antigen cross-presentation by bone marrow derived professional antigen presenting cells and identified the dominant MHC class-I restricted tumor rejection antigen, AH-1, in a murine colon tumor model.

Hosted by:
Executive Director of MIB Agents - Ann Graham OsteoWarrior and
MIB Junior Board Member - Shannon McCormack
MIB Super Volunteer Amy Woodchecke PA-C.

LINKS:
VIDEO of this Podcast: https://youtu.be/eRTS2S8li-I
BOWS: https://www.mibagents.org/bows
ANGEL WALL: In memory of OsteoAngels: https://www.youtube.com/watch?v=M6Cbe-1m72s&t=558s
     Note: Note: Dr. Huang's cousin, Wenwei is at 9:18
HUANG LAB: http://www.huanglab.com
Dr. Huang's Email: alex.y.huang@case.edu
Clinical Trial Search: www.mibagents.org/physicians-researchers/clinical-trials
…
What We Do at MIB Agents:
PROGRAMS:
✨ End-of-Life MISSIONS
✨ Gamer Agents
✨ Agent Writers
✨ Prayer Agents
✨ Healing Hearts Bereaved Parent Support
✨ Ambassador Agents - Peer Support
EDUCATION for physicians, researchers and families:
✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma
✨ MIB Book: Osteosarcoma: From our Families to Yours
RESEARCH:
✨ Annual MIB FACTOR Research Conference
✨ Funding $100,000 annually for OS research
✨ MIB Testing & Research Directory
✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard
...
Kids are still dying with 40+ year old treatments.   Help us MakeItBetter. 🔗 https://www.mibagents.org
✨✨SUBSCRIBE for all the Osteosarcoma Intel

Add a public comment...

OsteoBites welcomes Dr. Moyez Jiwa to discuss "The Art of Doctoring"

Dr. Jiwa is a practicing General Practitioner, Editor-in-Chief at the Journal Of Health Design, and an Associate Dean and Professor at the Melbourne Clinical School at the University of Notre Dame.

From Dr. Jiwa: "I bring experience from multiple roles- clinician, researcher, publisher, innovator and leader. What my experience has taught me is that healthcare professionals can achieve great results by focusing on what is in their immediate sphere of influence. In some of my roles, the only thing I got to choose was the color of my tie. Despite that, it has been possible to make a significant contribution to addressing many challenges for patients and providers of healthcare. I enjoy innovating and blogging while practicing the art of medicine."

Hosted by: Ann Graham OsteoWarrior and Executive Director of MIB Agents
Junior Board Members and OsteoWarriors: Mia and Maeve
....
LINKS Dr. Jiwa's Email: moyez.jiwa@nd.edu.au
OutRunning Osteosarcoma: www.mibagents.org/outrunning
Osteosarcoma Clinical Trial Search: www.mibagents.org/physicians-researchers/clinical-trials
…
What We Do at MIB Agents: PROGRAMS:
✨ End-of-Life MISSIONS
✨ Gamer Agents
✨ Agent Writers
✨ Prayer Agents
✨ Healing Hearts Bereaved Parent Support
✨ Ambassador Agents - Peer Support
EDUCATION for physicians, researchers and families:
✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma
✨ MIB Book: Osteosarcoma: From our Families to Yours
RESEARCH:
✨ Annual MIB FACTOR Research Conference
✨ Funding $100,000 annually for OS research
✨ MIB Testing & Research Directory
✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard
...
Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org✨
✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Osteosarcoma OsteoBites S2 Ep 18: Richard Gorlick, MD & Yifei Wang, MD “Antibody Drug Conjugates for Osteosarcoma”

MIB Agents Osteosarcoma OsteoBites S2 Ep 18: Richard Gorlick, MD & Yifei Wang, MD “Antibody Drug Conjugates for Osteosarcoma”
...
Guest Information:
Richard Gorlick, MD
Division Head, Department of Pediatrics
Professor, Department of Pediatrics Patient Care
Director, Department of Pediatric Sarcoma Research Laboratory
Department Chair, ad interim Sarcoma Medical Oncology, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center in Houston, TX

Dr. Richard Gorlick is Division Head and Department Chair of Pediatrics, Department Chair ad interim of Sarcoma Medical Oncology in the Division of Cancer Medicine at the MD Anderson Cancer Center, and H. Grant Taylor, M.D., W. W. Sutow, M.D. and Margaret P. Sullivan, M.D. Distinguished Chair in Pediatrics. Dr. Gorlick received his medical degree from Downstate Medical School. He trained at New York-Presbyterian and Memorial Sloan-Kettering Cancer Center, where he began his sarcoma research laboratory and clinical practice. His laboratory is the founding Bone Tumor Resource Laboratory for the Children’s Oncology Group. His molecular pharmacology laboratory is completely focused on osteosarcoma. His laboratory is a member of the NCI-funded Pediatric Preclinical Testing Consortium. Dr. Gorlick is involved in clinical trials, in part, as past chair of the Bone Tumor Disease Committee for COG. He is a past president of the Connective Tissue Oncology Society. Dr. Gorlick has published more than 260 peer-reviewed papers, reviews and book chapters and contributed to MIB Agent’s Testing and Research Directory to help inform a personal treatment plan or to inform research.
....
Hosted by:
Ann Graham OsteoWarrior and Executive Director of MIB Agents
Panelists:
Mia Sandino, OsteoWarrior and MIB Junior Board Member
Shannon McCormack, OsteoWarrior Sibling and MIB Junior Board Member
…
The next two weeks we will be taking a break first for July 4th weekend and then a short vacation.
...
LINKS
Richard Gorlick, MD RGorlick@MDanderson.org
Yeifei Wang, PhD YWang64@MDanderson.org
OutRunning Osteosarcoma: www.mibagents.org/outrunning
Osteosarcoma Clinical Trial Search:www.mibagents.org/physicians-researchers/clinical-trials
...
What We Do at MIB Agents:
PROGRAMS:
✨ End-of-Life MISSIONS
✨ Gamer Agents
✨ Agent Writers
✨ Prayer Agents
✨ Healing Hearts Bereaved Parent Support
✨ Ambassador Agents - Peer Support

EDUCATION for physicians, researchers and families:
✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma
✨ MIB Book: Osteosarcoma: From our Families to Yours

RESEARCH:
✨ Annual MIB FACTOR Research Conference
✨ Funding $100,000 annually for OS research
✨ MIB Testing & Research Directory
✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard
...

Kids are still dying with 40+ year old treatments. Help us MakeItBetter.
🔗 https://www.mibagents.org
✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Osteosarcoma OsteoBites S2 Ep 17: Lara Davis, MD, OHSU Knight Cancer Institute “New Osteosarcoma Clinical Trials”

MIB Agents OsteoBites S2 Ep 17: Lara Davis, MD, OHSU Knight Cancer Institute “New Osteosarcoma Clinical Trials”
...

Guest Information:
Lara E. Davis, MD
Associate Professor
Knight Cancer Institute
Co-Leader, Translational Oncology Research Program
Sarcoma Disease Site Leader
Oregon Health & Science University

Lara Davis, MD graduated from Wellesley College and then went on to receive her medical degree from OHSU. After training in a dual Internal Medicine and Pediatrics residency program at Harvard, she returned to Portland to complete a combined Adult and Pediatric Oncology fellowship with a focus on Adolescents and Young Adults (AYAs). Dr. Davis joined the faculty at OHSU in 2013, where she is a member of the Knight Cancer Institute with dual appointments in the Division of Medical Oncology and Pediatric Hematology/Oncology. She focuses exclusively on sarcoma in both the clinic and in the laboratory.
...
Hosted by:
Ann Graham OsteoWarrior and Executive Director of MIB Agents.
Panelists:
Annika Vallejo - MIB Junior Board Member & Osteosarcoma Sibling
Valerie Nguyen - MIB Junior Board Member & Osteosarcoma Sibling
…
Next week we will be talking with Dr. Richard Gorlick on “Antibody Drug Conjugates”, Dr. Gorlick is the Division Head, Division of Pediatrics, The University of Texas MD Anderson Cancer Center,
And Professor, Department of Pediatrics at The University of Texas MD Anderson Cancer Center, he is also a pediatric cancer survivor! We are looking forward to this conversation
...

LINKS
OutRunning Osteosarcoma: www.mibagents.org/outrunning
OutBidding Osteosarcoma: www.mibagents.org/outbidding
SarcTrials.org
More Information on trials discussed Email: SarcomaSurvivor@ohsu.edu
…
What We Do at MIB Agents:
PROGRAMS:

✨ End-of-Life MISSIONS

✨ Gamer Agents

✨ Agent Writers

✨ Prayer Agents

✨ Healing Hearts Bereaved Parent Support

✨ Ambassador Agents - Peer Support

EDUCATION for physicians, researchers and families:

✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma

✨ MIB Book: Osteosarcoma: From our Families to Yours

RESEARCH:

✨ Annual MIB FACTOR Research Conference

✨ Funding $100,000 annually for OS research

✨ MIB Testing & Research Directory

✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard

...

Kids are still dying with 40+ year old treatments. Help us MakeItBetter.

🔗 https://www.mibagents.org

✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Osteosarcoma OsteoBites S2 Ep 16: Julie Lanford, MPH, RD, CSO, LDN on “Nutrition & Cancer; Truths & Myths”

MIB Agents OsteoBites S2 Ep 16: Julie Lanford, MPH, RD, CSO, LDN a Registered Dietician who will be sharing her expertise on “Nutrition & Cancer Truths & Myths”
...
Guest Information:
Julie Lanford, MPH, RD, CSO, LDN
Wellness Director, Cancer Services

Julie received her degree in Biology from North Carolina State University and her Masters in public health nutrition from The University of North Carolina at Chapel Hill.

She is a registered dietitian, licensed nutritionist and board-certified specialist in oncology nutrition with 15 years experience. She can be found on her website CancerDietitian.com which translates evidence-based nutrition guidelines for everyday life.
...
Hosted by:
Ann Graham OsteoWarrior and Executive Director of MIB Agents.
…
Next week we will be talking with Dr. Lara Davis, Associate Professor and Sarcoma Program Director at Knight Cancer Institute at Oregon Health & Science University about NEW OSTEOSARCOMA CLINICAL TRIALS!
...
LINKS
OutRunning Osteosarcoma: www.mibagents.org/outrunning
OutBidding Osteosarcoma: www.mibagents.org/outbidding
Cancer Dietician Website: www.cancerdietician.org
Julie Lanford's Email: Julie@cancerdietician.com
American Cancer Society: www.cancer.org
American Institute for Cancer Research: www.AICR.org
Julie's BLOG: LINK
Tips for Bowel Regularity: LINK
Nutrition During Treatment Tips: https://www.cancerdietitian.com/tips
Webinars: https://www.cancerdietitian.com/webinars

…
What We Do at MIB Agents:
PROGRAMS:
✨ End-of-Life MISSIONS
✨ Gamer Agents
✨ Agent Writers
✨ Prayer Agents
✨ Healing Hearts Bereaved Parent Support
✨ Ambassador Agents - Peer Support
EDUCATION for physicians, researchers and families:
✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma
✨ MIB Book: Osteosarcoma: From our Families to Yours
RESEARCH:
✨ Annual MIB FACTOR Research Conference
✨ Funding $100,000 annually for OS research
✨ MIB Testing & Research Directory
✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard
...
Kids are still dying with 40+ year old treatments. Help us MakeItBetter.
🔗 https://www.mibagents.org

✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Osteosarcoma OsteoBites S2 Ep 15: Katie Greenzang, MD, EdM Dana-Farber CI & Harvard Med School “What’s Next? Survivorship"

MIB Agents OsteoBites S2 Ep 15: Katie Greenzang, MD, EdM from Dana-Farber Cancer Institute/Boston Children’s and Harvard Medical School. Dr. Greenzang will be talking about, “What’s Next? Osteosarcoma Survivorship”.
...
Guest Information:
Katie Greenzang, MD, MpH
Pediatric oncologist at Dana-Farber/Boston Children’s Hospital
Instructor at Harvard Medical School
...
Dr. Greenzang completed her pediatrics residency and chief residency at Seattle Children’s Hospital, and her fellowship training in pediatric hematology/oncology at the Dana-Farber Cancer Institute/Boston Children’s Hospital. Her research focuses on patient-provider communication and shared decision-making in children with cancer. She is particularly interested in understanding how families consider the short- and long-term effects of cancer therapies when making treatment decisions, and how we can improve communication about late effects of cancer therapy to help patients and families feel more prepared for cancer survivorship.
...
Panelists:
Kara Skrubis - MIB Junior Board Members and OsteoWarrior
Brandon Friendman - MIB Junior Board Members and OsteoWarrior
Maeve Smart - President of MIB Junior Board and OsteoWarrior
Ann Graham OsteoWarrior and Executive Director of MIB Agents
...
Next week we are taking a break in honor of Memorial Day, the week after we are off as well. We will be back on June 10th with a MUCH REQUESTED and NEEDED talk with Julie Lanford, on “Nutrition & Cancer Truths and Myths”.
...
LINKS
MIB Agents: Website
Register: https://bit.ly/3fACjuR
OutRunning Osteosarcoma:.mibagents.org/outrunning
OutBidding Osteosarcoma Contact: Ann@MIBagents.org

Osteosarcoma OsteoBites S2 Ep 14: Lillian Guenther, MD Dana-Farber CI & Harvard Med School “CRISPR Screening to Identify Novel Genomic Targets"

MIB Agents OsteoBites S2 Ep 14: Lillian Guenther, MD from Dana-Farber Cancer Institute and Harvard Medical School. Dr. Guenther will be talking about, “Utilizing CRISPR Screening to Identify Novel Genomic Targets for Osteosarcoma”
....
Guest Information:
Lillian Guenther, MD
Dana Farber Cancer Institute
...
Dr. Guenther received her bachelor degree from Brown University and her MD from SUNY Downstate College of Medicine. She spent one year as a Howard Hughes Medical Institute/NIH Research Scholar studying osteosarcoma in Dr. Lee Helman’s laboratory at the National Cancer Institute. Lily is currently an Instructor in Pediatrics at Harvard Medical School and performs research in the lab of Dr. Kimberly Stegmaier. She cares for pediatric cancer patients at Boston Children’s Hospital and in the Jimmy Fund Clinic at Dana-Farber Cancer Institute. Dr. Guenther was a finalist for our OutSmarting Osteosarcoma Grant. Our group of osteosarcoma families and Scientific Advisory Team found her research to be truly hopeful and innovative.
...
Panelists
Matt Allen, 2021 MIB Junior Board Member and Gamer Agents Leadership Team
Maeve Smart, OsteoWarrior & 2021 MIB Jr. Board President
Amy Woodchecke, Physician’s Assistant and Childhood Cancer Survivor.
Ann Graham, OsteoWarrior & Executive Director of MIB Agents.
...
Coming up next week, Dr. Katie Greenzang of Dana Farber Cancer Institute and Harvard Medical School on “What’s Next? Osteosarcoma Survivorship”
...
MIB Agents is a leading pediatric #osteosarcoma nonprofit dedicated to Making It Better for our
community of patients, caregivers, doctors, and researchers with the goal of less toxic, more effective treatments and a cure for this aggressive bone cancer. More information at www.mibagents.org
...
LINKS
Register: https://bit.ly/MIBobites
OutRunning Osteosarcoma:.mibagents.org/outrunning
Dr. Guenther Contact: Lillian_Guenther@dfci.harvard.edu

Osteosarcoma OsteoBites S2 E13: Scott Sauer, PhD on “Preventing Osteosarcoma Lethal Recurrence by Targeting Disseminated Tumor Cells”

MIB Agents OsteoBites S2 Ep 13: Scott Sauer, PhD on “Preventing Osteosarcoma Lethal Recurrence by Targeting Disseminated Tumor Cells”
...
Guest Information:
Scott Sauer, PhD
Head of Preclinical Discovery
Vuja De Sciences, Inc. (www.vujade-life.com)
...
Dr. Scott Sauer is a cancer researcher with multidisciplinary training in the fields of cancer biology, immunotherapy and organic chemistry. This diverse expertise provides a unique perspective to address unmet medical needs in cancer recurrence and metastasis. Scott received his PhD at Duke University in organic chemistry and a BS from the University of Maryland. After his PhD work, Dr. Sauer began his postdoctoral training at the Duke University Medical Center. His postdoctoral work was in cancer biology focusing on mechanisms of therapeutic resistance and disease progression. During this time, Scott received numerous postdoctoral awards including his work on the interplay between cancer progression and environmental toxicants. Dr. Sauer’s work was among the top three finalists for our 2021 OutSmarting Osteosarcoma grant.
...
Panelists
Kara Skrubis, MIB Junior Board Member and OsteoWarrior
Amy Woodcheke, Physician’s Assistant and Childhood Cancer Survivor
Ann Graham, OsteoWarrior & Executive Director of MIB Agents
...
What We Do PROGRAMS:
✨ End-of-Life MISSIONS
✨ Gamer Agents
✨ Warrior Mail
✨ Prayer Agents
✨ Healing Hearts Bereaved Parent Support
✨ Ambassador Agents - Peer Support

EDUCATION for physicians, researchers and families:
✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma
✨ MIB Book: Osteosarcoma: From our Families to Yours

RESEARCH
✨ Annual MIB FACTOR Research Conference
✨ Funding $100,000 annually for OS research
✨ MIB Testing & Research Directory
✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard
....
OsteoBites is made possible by listeners like you. Please consider donating to MIB Agents or be an All Star Agent by being a monthly supporter.
Kids are still dying with 40+ year old treatments. Help us MakeItBetter. www.mibagents.org
Osteosarcoma Resources: www.MIBagents.org/contact
Dr. Sauer Contact: scott.sauer@vujade-life.com
Vuja De Sciences: https://vujade-life.com/
MIB Limited Edition Sunflower Tee & Tank: https://www.bonfire.com/make-it-better-together/

Osteosarcoma OsteoBites S2 Ep12: Dan Prince, MD, MPH on “Regenerative Surgery for Bone Sarcomas”

MIB Agents OsteoBites S2 Ep12: Dan Prince, MD on “Regenerative Surgery for Bone Sarcomas”
...
Guest Information:
Daniel Prince, MD, MPH
Orthopedic Surgeon
Memorial Sloan Kettering Cancer
Education (MD): Yale University Medical School
Board Certifications: Orthopedic Surgery
...
Dr. Prince is an Orthopedic Surgeon from Memorial Sloan Kettering Cancer Center on the “MSK Kids” team, specializing in the care of children, adolescents, and young adults with bone tumors and other diseases of the bone. His research and expertise is in bone regeneration, which relies on the body’s natural abilities to regrow bone after a segment of bone is removed during cancer surgery.
...
MIB Agents is a leading pediatric #osteosarcoma nonprofit dedicated to Making It Better for our community of patients, caregivers, doctors, and researchers with the goal of less toxic, more effective treatments and a cure for this aggressive bone cancer. More information at www.mibagents.org
…
What We Do
PROGRAMS:

✨ End-of-Life MISSIONS

✨ Gamer Agents

✨ Warrior Mail

✨ Prayer Agents

✨ Healing Hearts Bereaved Parent Support

✨ Ambassador Agents - Peer Support

EDUCATION for physicians, researchers and families:

✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma

✨ MIB Book: Osteosarcoma: From our Families to Yours

RESEARCH

✨ Annual MIB FACTOR Research Conference

✨ Funding $100,000 annually for OS research

✨ MIB Testing & Research Directory

✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard

....
OsteoBites is made possible by listeners like you. Please consider donating to MIB Agents or be a Super Agent by being a monthly supporter. More info on our *New* website, mibagents.org
...
🔗
Kids are still dying with 40+ year old treatments. Help us MakeItBetter. www.mibagents.org
Daniel Prince, MD, MPH bit.ly/MIBprince
Memorial Sloan Kettering Cancer Center www.mskcc.org
OS Resource Kit Order Form www.mibagents.org - click on blue bar at top of page
...

Osteosarcoma OsteoBites S2 Ep 11: Ines Lohse, PhD on “Drug Sensitivity Testing for the Treatment Stratification of Cancer Patients”

MIB Agents OsteoBites S2 Ep 11: Ines Lohse, PhD on “Drug Sensitivity Testing for the Treatment Stratification of Cancer Patients”
...
Guest Information:
Ines Lohse, PhD
Assistant Scientist
University of Miami
Center for Therapeutic Innovation
...
Dr. Lohse received her PhD from the University of Zurich in 2011. After postdoctoral fellowships at the Princess Margaret Cancer Center (Toronto) and the University of Michigan, Dr. Lohse moved to the University of Miami to focus on the preclinical and early clinical development of novel technology and therapeutic options for cancer patients. The Ex Vivo Drug Sensitivity Testing Platform has been successfully tested in a pilot cohort of patients, including sarcoma. It is currently in development to transition the platform to clinical routine.
...
Panelists
Mia Sandino, MIB Junior Board Member and OsteoWarrior
Charlotte Murdoff, MIB Junior Board Member and OsteoWarrior
Annika Vallejo, MIB Junior Board Member and OsteoWarrior Sibling
Ann Graham, OsteoWarrior & Executive Director of MIB Agents.
...
Coming up next week is Daniel Prince, MD, MPH Orthopedic Surgeon from Memorial Sloan Kettering Cancer Center on
“Regenerative Surgery for Bone Sarcomas”.
...
MIB Agents is a leading pediatric #osteosarcoma nonprofit dedicated to Making It Better for our
community of patients, caregivers, doctors, and researchers with the goal of less toxic, more effective treatments and a cure for this aggressive bone cancer. More information at www.mibagents.org
...
Register: https://bit.ly/MIBobites
Osteosarcoma Resources: www.MIBagents.org/contact
Dr. Lohse Contact: ixl180@med.miami.edu
University of Miami Website: umiamihealth.org/sylvester-comprehensive-cancer-center/research/faculty/ines-lohse-phd

Osteosarcoma OsteoBites S2 Ep 10: Sumit Gupta, MD, PhD, FRCPC “Long Term Mental Health Outcomes in Adolescents and Young Adults with Cancer”

MIB Agents OsteoBites S2 Ep 10: Sumit Gupta, MD, PhD, FRCPC “Long Term Mental Health Outcomes in Adolescents and Young Adults with Cancer”
...
Guest Information:
Sumit Gupta, MD, PhD, FRCPC
Hospital for Sick Children, Staff Oncologist and Clinician Investigator
University of Toronto, Associate Professor
Institute for Health Policy, Management and Evaluation, Associate Professor
Cancer Research Program at the Institute for Clinical Evaluative Sciences, Adjunct Scientist

Dr. Gupta completed a PhD in Clinical Epidemiology from the University of Toronto, during which time he was supported by a CIHR Fellowship Award. He is one of the Assistant Chairs of the Lancet Oncology Commission on Sustainable Pediatric Cancer Care in low and middle income countries. Sumit has worked extensively with pediatric oncologists and policymakers throughout Latin America, the Caribbean, and India. He currently holds grant funding from The Garron Family Cancer Centre, CIHR and the Terry Fox Research Institute.Sumit Gupta, MD, PhD, FRCPC
...
Panelists
Amy Woodcheke, Physicians Assistant and Childhood Cancer Survivor
Mia Sandino, MIB Junior Board Member and OsteoWarriors
Ann Graham, OsteoWarrior & Executive Director of MIB Agents
...
Coming up next week is Dr. Ines Lohse of University of Miami, Sylvester Comprehensive Cancer Center talking with us about “Drug Sensitivity Testing for the Treatment Stratification of Cancer Patients”
...
MIB Agents is a leading pediatric #osteosarcoma nonprofit dedicated to Making It Better for our community of patients, caregivers, doctors, and researchers with the goal of less toxic, more effective treatments and a cure for this aggressive bone cancer. More information at www.mibagents.org
...
Register: https://bit.ly/MIBobites
Osteosarcoma Resources: www.MIBagents.org/contact
Link Mentioned on this episode on ASCO BLOG: Addressing the Mental Health Needs of Adolescent and Young Adult Cancer Survivors
https://connection.asco.org/blogs/addressing-mental-health-needs-adolescent-and-young-adult-cancer-survivors

MIB Agents OsteoBites S2 Ep 9: Jane Yanagawa, MD, “Osteosarcoma Lung Metastases”

Guest Information:
Jane Yanagawa, MD
Associate Professor of Thoracic Surgery,
UCLA David Geffen School of Medicine, Department of Surgery
...
Dr. Yanagawa is a thoracic surgeon at the UCLA David Geffen School of Medicine, Department of Surgery. She completed her residency at UCSD and her fellowship in Thoracic Surgery at Memorial Sloan-Kettering Cancer Center.
...
Our panel today includes Amy Woodcheke, Physicians Assistant and Childhood Cancer Survivor. And MIB Junior Board Members and OsteoWarriors Mia Sandino and Charlotte Murdoff. I am your host, Ann Graham Executive Director of MIB Agents.
...
Coming up next week is Sumit Gupta, MD, PhD who will be speaking on “Long Term Mental Health Outcomes in Adolescents and Young Adults with Cancer”
...
MIB Agents is a leading pediatric #osteosarcoma nonprofit dedicated to Making It Better for our
community of patients, caregivers, doctors, and researchers with the goal of less toxic, more effective treatments and a cure for this aggressive bone cancer. More information at www.mibagents.org
...
Register: https://bit.ly/MIBobites
Osteosarcoma Resources: www.MIBagents.org/contact

OsteoBites S2 Ep 8: Chand Khanna DVM, PhD, “A Comparative Approach To Metastasis: Biology and Therapy”

MIB Agents OsteoBites S2 Ep 8: Chand Khanna DVM, PhD, “A Comparative Approach To Metastasis: Biology and Therapy”

Guest Information:
Chand Khanna DVM, PhD
Chief Science Officer, Ethos Veterinary Health
President, President of Ethos Discovery

Dr. Khanna is a well known osteosarcoma expert and researcher. He is a board-certified diplomate of the American College of Veterinary Internal Medicine (Oncology) and an honorary Diplomate of the American College Veterinary Pathology. He received a PhD in Pathobiology from the University of Minnesota and then completed a postdoctoral fellowship in the Pediatric Oncology Branch of the National Cancer Institute where he led a laboratory focused on metastasis drug discovery and was the founding director of the NCI Comparative Oncology Program. Dr. Khanna is Chief Science Officer with Ethos Veterinary Health, and President of Ethos Discovery, a nonprofit incubator of scientific innovation.
...
Our panel today includes Amy Woodchecke BS, MHS, PA-C,, a childhood cancer survivor and pediatric oncology Physician’s Assistant. I am your host, Ann Graham Executive Director of MIB Agents.
...
Coming up in April with OsteoExperts Making It Better including; Jane Yanagawa, MD, Sumit Gupta, MD, PhD, Ines Lohse, PhD and Daniel Prince, MD.
...
MIB Agents is a leading pediatric #osteosarcoma nonprofit dedicated to Making It Better for our
community of patients, caregivers, doctors, and researchers with the goal of less toxic, more effective treatments and a cure for this aggressive bone cancer. More information at www.mibagents.org
...
Register: https://bit.ly/MIBobites
Osteosarcoma Resources: www.MIBagents.org/contact
Contact Dr. Khanna via Ethos Vet: ckhanna@ethosvet.com or Donna Reis at dreiss@ethosvet.com

OsteoBites S2 Ep7: Corrie Painter, PhD “The Osteosarcoma Project, Patient-Partnered Research Update”

MIB Agents OsteoBites S2 Ep7: Corrie Painter, PhD “The Osteosarcoma Project, Patient-Partnered Research Update”

Guest Information:
Corrie Painter, PhD
Deputy Director, Count Me In. OSProject.org
Broad Institute of MIT & Harvard

Corrie Painter, PhD is the Associate Director of Count Me In and is a research scientist at the Broad Institute of MIT and Harvard. A trained cancer researcher with a Ph.D. in biochemistry, she completed her postdoctoral work in cancer immunology, focused on melanoma. In 2010, Painter was diagnosed with angiosarcoma. She has combined her cancer advocacy and scientific background to engage with patients in order to build and carry out patient-partnered genomics studies. She is also the co-founder of Angiosarcoma Awareness Inc.

...

Our panel today includes 2021 MIB Junior Board Member Shannon McCormack, 2020 Junior Board Member Ryan Kennington and Amy Woodchecke BS, MHS, PA-C,, a childhood cancer survivor and pediatric oncology Physician’s Assistant. I am your host, Ann Graham Executive Director of MIB Agents.

...

Panelists Information:
Amy Woodcheke, BS, MHS, PA-C
Shannon McCormack, 2021 MIB Junior Board Member & OsteoWarrior Sibling
Ryan Kennington, 2020 MIB Junior Board Member & OsteoWarrior
Hosted By Ann Graham, MIB AgentsExecutive Director & OsteoWarrior
...

The rest of March, we will be taking a break. April is packed with OsteoExperts Making It Better including; Chand Khanna, DVM, PhD, Jane Yanagawa, MD, Sumit Gupta, MD, PhD, Ines Lohse, PhD and Daniel Prince, MD.

...

MIB Agents is a leading pediatric #osteosarcoma nonprofit dedicated to Making It Better for our
community of patients, caregivers, doctors, and researchers with the goal of less toxic, more effective treatments and a cure for this aggressive bone cancer. More information at www.mibagents.org

...

Register: https://bit.ly/MIBobites

OsteoBites S2 Ep6: Brian Van Tine, MD, PhD on “Osteosarcoma Tumor Metabolism”

MIB Agents OsteoBites S2 Ep6: Brian Van Tine, MD, PhD on “Osteosarcoma Tumor Metabolism”

Guest Information:

Brian Van Tine, M.D., Ph.D.
Associate Professor of Medicine
Associate Professor of Pediatrics
Washington University in St Louis, Missouri
Sarcoma Program Director
Co-Director of the Adolescence and Young Adult Program
Alvin J. Siteman Cancer Center.

Dr. Van Tine has been the head of the Sarcoma Clinical Trials Program at Washington University for the past decade. Dr. Van Tine’s laboratory is dedicated to understanding the metabolism of sarcoma, and has recently developed a dual metabolic therapy for the treatment of complex cytogenetic sarcomas based on the exploitation of argininosuccinate synthetase 1 deficiency and glutaminase inhibition.
...
MIB Agents is a leading pediatric #osteosarcoma nonprofit dedicated to Making It Better for our community of patients, caregivers, doctors, and researchers with the goal of less toxic, more effective treatments and a cure for this aggressive bone cancer. More information at www.mibagents.org
…

What We Do at MIB Agents:
PROGRAMS:

✨ End-of-Life MISSIONS
✨ Gamer Agents
✨ Agent Writers
✨ Prayer Agents
✨ Healing Hearts Bereaved Parent Support
✨ Ambassador Agents - Peer Support

EDUCATION for physicians, researchers and families:
✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma
✨ MIB Book: Osteosarcoma: From our Families to Yours

RESEARCH:
✨ Annual MIB FACTOR Research Conference
✨ Funding $100,000 annually for OS research
✨ MIB Testing & Research Directory
✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard

....
OsteoBites is made possible by listeners like you. Please consider donating to MIB Agents or be a Super Agent by being a monthly supporter. More info on our *New* website, mibagents.org
...

Kids are still dying with 40+ year old treatments. Help us MakeItBetter.

🔗 https://www.mibagents.org

MIB Agents OsteoBites

By Ann Graham

Available on